Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Aponermin Injection in Relapsed Multiple Myeloma
ChiCTR2500103856Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Jun 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aponermin in multiple myeloma (MM), sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoints: M protein value, Overall response rate and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
aponermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500103856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103856.